Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.31 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27247376 | 0.98 | EPHX2 (0.36) | EPHX2CYP2C9CYP2J2MAPK1KIT | |
| SCHEMBL30946183 | 0.88 | MAPK1 (0.34) | MAPK1DGAT2 | |
| SCHEMBL27247511 | 0.88 | EPHX2 (0.37) | EPHX2CYP2C9CYP2J2MAPK1KIT | |
| SCHEMBL27247742 | 0.87 | KLKB1 (0.31) | — | |
| SCHEMBL27247517 | 0.86 | PDCD1 (0.34) | EPHX2CYP2C9CYP2J2MAPK1DGAT2 | |
| SCHEMBL27247302 | 0.86 | MAPK1 (0.34) | MAPK1DGAT2 | |
| SCHEMBL30946210 | 0.86 | PDCD1 (0.34) | EPHX2CYP2C9CYP2J2MAPK1DGAT2 | |
| SCHEMBL30946178 | 0.86 | MAPK1 (0.34) | MAPK1DGAT2 | |
| SCHEMBL27247138 | 0.86 | EPHX2 (0.37) | EPHX2CYP2C9CYP2J2MAPK1KIT | |
| SCHEMBL27247685 | 0.86 | EPHX2 (0.37) | EPHX2CYP2C9CYP2J2MAPK1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601635-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
| WO-2024081748-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | EPHX2 3370/4885CYP2C9 302/4885CYP2J2 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.